Table 4.
Multivariable Cox regression for bloodstream infection in liver transplant recipients.
| Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age, years | 1.00 (0.98–1.02) | 0.907 | ||
| Male sex | 0.64 (0.40–1.01) | 0.055 | ||
| Underlying disease | ||||
| Alcoholic | 0.85 (0.51–1.39) | 0.511 | ||
| Viral hepatitis | 1.10 (0.68–1.77) | 0.709 | ||
| Hypertension | 0.58 (0.29–1.14) | 0.115 | ||
| Diabetes | 1.10 (0.68–1.77) | 0.710 | ||
| Cardiovascular disease | 1.41 (0.72–2.74) | 0.314 | ||
| HCC | 1.53 (0.92–2.55) | 0.100 | ||
| High MELD | 1.76 (1.11–2.80) | 0.017 | 1.49 (0.91–2.44) | 0.116 |
| Donor age, years | 1.01 (1.00–1.03) | 0.087 | ||
| Donor sex, male | 1.19 (0.73–1.93) | 0.494 | ||
| Donor BMI, kg/m2 | 1.09 (1.01–1.19) | 0.035 | 1.10 (1.01–1.20) | 0.029 |
| ABO incompatibility | 0.82 (0.37–1.81) | 0.626 | ||
| Living donor | 0.66 (0.40–1.07) | 0.094 | ||
| Rejection | 2.28 (1.24–4.20) | 0.008 | 2.51 (1.32–4.78) | 0.005 |
| Desensitization | ||||
| Rituximab | 0.84 (0.40–1.77) | 0.655 | 0.70 (0.31–1.57) | 0.380 |
| Plasmapheresis | 0.89 (0.43–1.87) | 0.760 | ||
| Surgery time, hr | 1.06 (0.94–1.20) | 0.326 | ||
| Cold ischemia time, hr | 1.09 (0.99–1.21) | 0.087 | ||
| RBC transfusion, pack | 1.05 (1.02–1.08) | 0.001 | 1.05 (1.01–1.09) | 0.007 |
| Pre-LT HGG | 2.15 (0.89–5.23) | 0.090 | ||
| Post-LT HGG | 2.19 (1.08–4.45) | 0.030 | 1.46 (0.53–4.06) | 0.463 |
Post-LT HGG was assessed at postoperative 1 month. Post-LT HGG and rejection were used as time-varying variables. HGG was defined as a measured IgG level of < 700 mg/dL7.
BMI, body mass index; CI, confidence interval; HCC, hepatocellular carcinoma; HGG, Hypogammaglobulinemia; HR, hazard ratio; LT, liver transplantation; MELD, model for end-stage liver disease; RBC, red blood cell.